Dr Samir Agrawal is a Consultant Haemato-Oncologist at St Bartholomew’s Hospital and The Barts Health NHS Trust and a Senior Lecturer in Haematology at Queen Mary University of London. He also sees patients privately, including at Leaders in Oncology Care.
Dr Agrawal has expertise is in the treatment of blood cancers and in stem cell transplantation for these diseases and a specialist interest in chronic lymphocytic leukaemia (CLL). He is also a recognised expert in the field of infections in immunocompromised patients with cancer and a world authority on life-threatening invasive fungal infections.
Dr Agrawal qualified at the University of Bristol and then trained at the Royal Marsden Cancer Hospital. He was awarded a PhD with first class with honours (in Immunology) at the University of Paris. He is a former Director of The Stem Cell Laboratory and Head of Diagnostic Immunophenotyping. Dr Agrawal has designed, funded, and implemented studies on myelodysplastic syndromes, invasive aspergillosis, and chronic lymphocytic leukaemia (CLL). He was a founding Trustee of the UK MDS group and formerly a member of the UK MDS and CLL trials committee. He is also a trustee for CLLSA, the patient-led support organisation for patients in the UK with CLL, as well as a NICE reviewer and the Haemato-Oncology representative on the UK IVIg initiative.
Dr Agrawal's current activities are in the field of invasive fungal disease, chronic lymphocytic leukaemia, systems for ‘remote care’ for patients and can empower patients by giving them their data through secure online databases. He is also a member of the fungal subgroup for the government committee on antimicrobial resistance, ESPAUR.